Recent Updates
Recently added Catalysts
BMRN

BioMarin to Attend Upcoming Investor Conference BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in...

Key Takeaway: SAN RAFAEL, Calif. , May 2, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Health Care Conference on May 15, 2018 at 10:40a

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
7.9%
average across 8 past catalysts
Lead asset
Valoctocogene roxaparvovec
Phase 3 · Hemophilia A

Full Press Release Details

SAN RAFAEL, Calif. , May 2, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Health Care Conference on May 15, 2018 at 10:40am PT / 1:40pm ET in Las Vegas. To access the live webcast, please visit the investor section of the BioMarin website, www.biomarin.com . A replay will also be archived on the site for at least one week following each event.
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.
Contacts:
Investors Media
Traci McCarty Debra Charlesworth
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (415) 455-7451
Last updated: May 2, 2018